denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.
Program: Education Program
Hematology Disease Topics & Pathways:
Hemoglobinopathies, Diseases, Treatment Considerations, Study Population
Hematology Disease Topics & Pathways:
Hemoglobinopathies, Diseases, Treatment Considerations, Study Population
Monday, December 9, 2024: 10:30 AM-11:45 AM
Room 31
(San Diego Convention Center)
Description:
This session will discuss the current state of therapies for sickle cell disease in Africa. Access barriers to disease-modifying and curative treatments for sickle cell anemia will be identified, and recommendations of strategies to address some of these barriers will be proposed. The case will be made to prioritize widespread use of hydroxyurea therapy as the bedrock of sickle cell anemia care in Africa.
Chair:
Isaac Odame, MBBCh, The Hospital for Sick Children (SickKids) and the University of Toronto
Disclosures:
Odame: Pfizer: Other: Data Safety Monitoring Board; Novo Nordisk: Honoraria; Vertex: Other: Adboard; Novartis: Research Funding.
This session will discuss the current state of therapies for sickle cell disease in Africa. Access barriers to disease-modifying and curative treatments for sickle cell anemia will be identified, and recommendations of strategies to address some of these barriers will be proposed. The case will be made to prioritize widespread use of hydroxyurea therapy as the bedrock of sickle cell anemia care in Africa.
See more of: Education Program